3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Terminated
1
Recruiting
1
No longer available
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
12
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
5
Neoplasm Metastasis
5
Pancreatic Neoplasms
4
Colorectal Neoplasms
3
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Thrombocytosis
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
12
aldesleukin
9
fludarabine
8
fludarabine phosphate
7
pembrolizumab
6
Ipilimumab
5
Interleukin-2
5
Nivolumab
4
dabrafenib
2
Vemurafenib
2
Biopsy
2
Aminolevulinic Acid
2
varlilumab
1
trametinib
1
tilsotolimod
1
spartalizumab
1
sotigalimab
1
sonidegib
1
smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic
1
glembatumumab vedotin
1
eprenetapopt
1
epacadostat
1
encorafenib
1
cemiplimab
1
cabozantinib
1
binimetinib
1
bempegaldesleukin
1
abobotulinumtoxinA
1
X-Rays
1
Tranexamic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Skin Neoplasms
×
trametinib
×
Clear all
NCT02967692
2025-09-18
COMBI-i
Novartis
Phase 3
Terminated
568 enrolled
28 charts